img 614-636-4850
  • Follow us:
Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF


Dublin, OH (Aril 8, 2015) - Eli Lilly has recognized Dublin, Ohio based Biosortia Pharmaceuticals with the 2014 Open Innovation Drug Discovery (OIDD) Collaborator of the Year award.

The Collaborator of the Year award is the result of the innovative results and progress created by Biosortia and Lilly's OIDD team.

Biosortia, a leader in discovering and co-develop novel and potent bio-active compounds, is primarily focused on drug discovery for cancer, infectious disease, and anti-inflammatory therapeutics. Since entering Lilly's OIDD program in 2012, Biosortia has nearly 100% acceptance of the compounds it has submitted, far exceeding the 40% to 50% average of all other providers combined.

"Lilly's OIDD program and the innovation that their team develops has created an opportunity for Biosortia to provide Lilly with the type of chemistry they are seeking... new, highly potent chemistry, resulting in new mechanisms of action," says Dr. Guy Carter, Biosortia's Chief Science Officer. Carter, formerly head of Natural Products Discovery at Wyeth Pharmaceuticals, leads Biosortia's internationally renowned collaborative scientific team that aquatic microbial consortia containing vast chemistry diversity that elicits a wide range of biological effects. Biosortia accesses this new chemistry from previously inaccessible aquatic ecosystems.

"Lilly's recognition of our collaborative relationship further validates the importance of our distinct capability to provide our customers an important recurring pipeline of novel chemistry they are seeking and to assist in the co-development of these important optimized leads for their drug discovery pipeline. The highly innovative team of professionals within Lilly's OIDD program has led to an important collaboration relationship," says Biosortia President and CEO, Kurt Dieck.

To date Biosortia has research agreements with 4 top big pharma companies with more in the pipeline and is planning to release its next fraction library to Lilly and others in late April 2015.



About Biosortia Pharmaceuticals - Biosortia Pharmaceuticals is is a division of Algaeventure Systems (AVS). Biosortia has a proven and unique ability to obtain unculturable aquatic microorganism consortia from the natural environment in unprecedented quantities that allows its research team to perform direct study of vast quantities of new natural products. Biosortia is actively engaging drug research and development organizations to explore the vast opportunity of unculturable microorganisms for potential therapeutic agents, and other novel compounds of value in biotechnology fields.